Skip to main content
Caplight Logo









Adaptyv Bio

Adaptyv Bio

Private
Epalinges, VaudHealthcare & Life Scienceshttps://adaptyvbio.com

Last Round

Series A

Aug 26, 2026

Total Funding Raised

$50.85M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Adaptyv Bio operates in Healthcare & Life Sciences and is based in Epalinges, Vaud. Its latest recorded funding round was a Series A round in August 2026.

Adaptyv Bio is a biotechnology company that develops a next-generation protein engineering foundry integrating artificial intelligence, robotics, and nanofluidics to accelerate the design, synthesis, and testing of novel proteins.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment, ML Platforms

Business Model

B2B

Customer Profile

Usage-Based SaaS

AI Layer

Infrastructure

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Adaptyv Bio Comparables

Compare Adaptyv Bio with similar companies based on industry and business-model similarity.

Adaptyv Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ailurus Biotechnology
79%
Arctoris
78%
Tierra Biosciences
78%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Adaptyv Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AAug 26, 2026
SeedSep 25, 2025
DebtJun 1, 2023
Pre SeedFeb 14, 2022
SeedAug 4, 2021
Grant
Apr 28, 2021
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Julian Englert

Co-Founder And CEO

Founding Team

For institutional investors. Book with your work email.

Adaptyv Bio Investors

Notable investors and investment history

Book a demo to see all 17 investors

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 26, 2026

    $40M round led by Highland Europe.

  • Apr 18, 2026

    Added Cradle, a biotechnology/AI startup, as a customer.

Book a demo to see all signals

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

  • has_revenueSep 2, 2026

    Adaptyv Bio records an estimated $2.6M in revenue in Dec '24.

  • receives_financingAug 29, 2026

    Adaptyv Bio recently receives a $46.6M Series A led by Highland Europe, with participation from ACE Ventures, byFounders and Y Combinator, to expand its full-stack platform for AI-enabled protein engineering in Switzerland.

  • receives_financingAug 27, 2026

    Adaptyv Bio raised a $40M Series A on Aug 27th '26 in Switzerland, led by Highland Europe with existing investors Ace Ventures, ByFounders, and Y Combinator, to build an automated lab for AI-driven protein design.

  • integrates_withAug 27, 2026

    Adaptyv Bio's publicly available API integrates with Boltz and lets AI agents order experiments directly through its automated lab in Aug '26.

  • expands_facilitiesAug 27, 2026

    Adaptyv Bio announces a facility expansion in Lausanne as it plans to roughly triple its lab capacity by the end of 2026, alongside a new lab and office opening in London in Q4 '26.

Book a demo to see all news

For institutional investors. Book with your work email.

Adaptyv Bio Filings

Explore SEC and related filing metadata, where available.

Adaptyv Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Adaptyv Bio's valuation, stock price, and market status.

Is Adaptyv Bio a public or private company?

Adaptyv Bio is a private company.

What is the current stock price of Adaptyv Bio?

Adaptyv Bio is a private company, so its shares have no public market price. Caplight tracks Adaptyv Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Adaptyv Bio worth (valuation)?

Valuation information for Adaptyv Bio is not publicly available.

Can I buy Adaptyv Bio stock?

Adaptyv Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Adaptyv Bio's last funding round?

Adaptyv Bio's most recent funding round was Series A on August 26, 2026.

Who are the main investors in Adaptyv Bio?

Key investors in Adaptyv Bio include ACE Ventures, ACE Ventures, Highland Europe, Founderful.

Will Adaptyv Bio IPO soon?

No public IPO plans have been announced for Adaptyv Bio.

How can I track Adaptyv Bio secondary market activity?

Caplight tracks bids, offers, and trades in Adaptyv Bio's shares on secondary markets.

Firmographic Details

HeadquartersEpalinges, Vaud
Employee Range32
Year Founded2021
Last FundingAug 26, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?